NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

Home・Aandelen Lijst・Roche Holding AG

Roche Holding AG

Open

SectorGezondheidszorg

370.8 1.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

362.8

Max

369.6

Belangrijke statistieken
By Trading Economics
Inkomsten	1.8B 5.5B
Verkoop	15B 31B
K/W Sectorgemiddelde	23.041 108.767
Dividendrendement	2.63
Winstmarge	17.892
Werknemers	103,249
EBITDA	5.1B 12B

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	2.63% 2.21%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	5.3B 294B
Vorige openingsprijs	369.54
Vorige sluitingsprijs	370.8

Nieuwssentiment

By Acuity

100%

333 / 352 Rangschikking in Healthcare

Roche Holding AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 jan 2026, 10:07 UTC

Winsten

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29 jan 2026, 07:07 UTC

Winsten

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18 nov 2025, 11:04 UTC

Belangrijke Marktbewegers

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23 okt 2025, 09:32 UTC

Winsten

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23 okt 2025, 05:54 UTC

Winsten

Roche Raises Full-Year Earnings Outlook

3 mrt 2026, 07:22 UTC

Marktinformatie

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2 mrt 2026, 14:21 UTC

Marktinformatie

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29 jan 2026, 11:40 UTC

Marktinformatie

Winsten

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29 jan 2026, 06:05 UTC

Winsten

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29 jan 2026, 06:04 UTC

Winsten

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29 jan 2026, 06:03 UTC

Winsten

Roche Issues 2026 View

29 jan 2026, 06:02 UTC

Winsten

Analysts Saw 2025 Core EPS at CHF19.70

29 jan 2026, 06:02 UTC

Winsten

Roche: 2025 Core EPS CHF19.46

29 jan 2026, 06:01 UTC

Winsten

Analysts Had Seen 2025 Sales At CHF61.47B

29 jan 2026, 06:01 UTC

Winsten

Roche 2025 Sales CHF61.52B

28 jan 2026, 11:22 UTC

Winsten

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27 jan 2026, 11:31 UTC

Marktinformatie

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27 jan 2026, 11:24 UTC

Marktinformatie

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27 jan 2026, 09:30 UTC

Marktinformatie

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27 jan 2026, 07:52 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Roche Obesity Study Data Look Encouraging -- Market Talk

16 jan 2026, 17:03 UTC

Marktinformatie

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12 jan 2026, 14:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Pharma Sector Can Spend Big on M&A -- Market Talk

22 dec 2025, 08:48 UTC

Marktinformatie

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19 nov 2025, 12:47 UTC

Marktinformatie

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10 nov 2025, 12:16 UTC

Marktinformatie

Winsten

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23 okt 2025, 09:19 UTC

Marktinformatie

Winsten

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23 okt 2025, 09:11 UTC

Marktinformatie

Winsten

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23 okt 2025, 05:09 UTC

Winsten

Roche 3Q Sales Up 6% At CER

23 okt 2025, 05:07 UTC

Winsten

Roche 3Q Sales CHF14.92B

23 okt 2025, 05:07 UTC

Winsten

Analysts Had Seen 3Q Sales At CHF15.17B

Peer Vergelijking

Prijswijziging

Roche Holding AG Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Roche Holding AG - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

333 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.